What changed · written from our data
As of Nov 5, 2026Azora Therapeutics closed at $3.71 on Nov 5, down 8.40%, within 0.0% of its lowest close since Oct 29.
Azora Therapeutics, Inc. Common Stock (AZR)
$3.71−8.40%
Close Nov 5, 2026 · split-adjustedNov 5, 2026$3.71▼ 23.98% in range
Oct 29, 2026Low $3.71 · High $4.88Nov 5, 2026
Market cap$9.7M2.6M shares
Revenue · quarter——
Diluted EPS——
P/E · TTM—
Net margin—
Dividend yieldNone
Range since Oct 293.71 – 4.88−24.0% from high
Volume18.6K
Volatility · 60d—Annualised
Short % of float—
Net cash—
Next earnings—Not scheduled
Split-adjusted performance
1W −24.0%1M —3M —6M —YTD —1Y —3Y —5Y —Earnings reactions
History →No reported quarters with price history yet.
Rank within Pharmaceuticals
Percentile among 420 companies (100 = best)
6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size16
Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.
Short interest
Details →No short interest reported.
Closest peers by size in Pharmaceuticals
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AZRAzora Therapeutics | $3.71 | −8.40% | — | — | — | — | $9.7M | |
| RKTORocket One | $0.4020 | −9.09% | — | — | — | — | $10.0M | Compare |
| ASBPAspire-Lakewood Holdings | $6.76 | −7.52% | +45.4% | — | −2009.6% | — | $9.5M | Compare |
| PTNPalatin Technologies | $5.71 | −5.15% | −69.8% | — | −1449.1% | — | $10.2M | Compare |
| PHIOPhio Pharmaceuticals | $0.8000 | −8.04% | −29.8% | — | — | — | $9.3M | Compare |
| BFRGBullfrog AI Holdings | $0.4931 | −6.31% | −24.1% | +547.6% | −636.8% | — | $9.1M | Compare |
| CURXCuranex Pharmaceuticals | $5.78 | −0.34% | −8.4% | — | — | — | $9.1M | Compare |
| BIVIBioVie | $1.21 | −9.70% | −21.4% | — | — | — | $10.5M | Compare |
| MBRXMoleculin Biotech | $8.73 | +3.19% | −82.5% | — | — | — | $8.9M | Compare |
News about Azora Therapeutics
All news →No recent articles focused on Azora Therapeutics.
Quick answers
- What does Azora Therapeutics do?
- Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor.
- What is AZR's market cap?
- $9.74M, based on the Nov 5 close of $3.71.
- What sector is AZR in?
- Healthcare, in the Pharmaceuticals industry.
About Azora Therapeutics
Azora Therapeutics Inc is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. Azora owns the royalty-free rights to its technology, which is based on the development of potential best-in-class oral agonists of the aryl hydrocarbon receptor. Azora's lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology